Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jun 25, 2009

Premium

Title: Method of Isolating, Labeling, and Profiling Small RNAs

Number: 7,550,583

Filed: April 28, 2005

Inventor: Xueliang Xia, Geno Sensor

The patent, its abstract states, claims "a method of selectively labeling non-messenger RNA molecules by isolating total RNA from a tissue or cell, dissolving the isolated RNA, blocking the 3' end of the RNA, and adding T4 RNA ligase and a labeled nucleic acid adaptor."

Through this process, "the T4 RNA ligase ligates the adaptor only to RNA having a 5' phosphate group and only small RNA are labeled," the abstract notes. "A method of labeling the 5' end of mRNA isolates total RNA from a tissue or cell, dissolving RNA in RNase-free water; removing a 5' cap structure from the mRNA using tobacco acid pyrophosphatase; removing the TAP; blocking the 3' end of the RNA molecules; and ligating an adaptor to the RNA by adding T4 RNA ligase and a labeled DNA or RNA adaptor."

Another embodiment of the invention comprises a method of profiling small RNA expression by "separating labeled RNA from capped RNA; providing a microarray comprising a plurality of probes hybridizable to small RNA; incubating the labeled small RNA with the microarray; washing unhybridized RNA from the microarray and drying the microarray; staining hybridized RNA on the microarray; and scanning the labeled microarray to determine the identity and quantity of labeling to the various miRNA probe sites and thus providing an expression profile of small RNA," the abstract adds.


Title: RNA Interference-Mediating Small RNA Molecules

Number: 20090155174

Filed: Oct. 29, 2008

Lead Inventor:
Thomas Tuschl, Max Planck Institute

"Double-stranded RNA induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference," the patent application's abstract states "Using a Drosophila in vitro system, we demonstrate that 19-23 [nucleotide long] short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3' ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA," the abstract notes. "Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNA complex."


Title: Method of Inhibiting Expression of a Target mRNA Using siRNA Consisting of Nucleotide Sequence Complementary to Said Target mRNA

Number: 20090155904

Filed: Dec. 8, 2005 PCT Filed: Dec. 8, 2005

Lead Inventor: Young-Chul Choi, Bioneer

The patent application, its abstract states, claims a method to inhibit target mRNA expression by "obtaining binding energy of a double combination section on a dsRNA sequence of all [combinations] comprising complementary nucleotides to a random target mRNA; dividing the binding energy into four sections on the dsRNA sequence of each combination to obtain a difference of the mean binding energy between each section and [converting ]into a score of a relative combination energy pattern; selecting siRNA whose inhibition efficiency to target mRNA is expected to be high by applying the converted score to the dsRNA sequence with other factors that affect the efficiency of siRNA; and inhibiting target mRNA expression using the selected siRNA.

"As a result, a researcher or an experimenter can analyze patterns of a relative binding energy on base sequences of unknown siRNA without actual experiments to determine whether the siRNA is effective or ineffective rapidly, thereby design and production efficiency of siRNA can be maximized and target mRNA can be effectively inhibited with efficient siRNA to the target mRNA," it adds.


Titles: Down-Regulating of Gene Expression Using Artificial microRNAs

Numbers: 20090155909, 20090155910

Filed: Dec. 16, 2008

Inventor: Brian McGonigle, DuPont

The patent applications, their abstracts state, claim "isolated nucleic acid fragments comprising precursor miRNA, and artificial miRNAs and their use in down-regulating gene expression."


Title: Interfering RNA Delivery System and Uses Thereof

Number: 20090156470

Filed: Dec. 18, 2008

Inventor: Jon Chatterton, Alcon

"The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule," the patent application's abstract states. "The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro … [and] therapeutic uses for the delivery system are also provided."


Title: Novel siRNAs and Methods of Use Thereof

Number: 20090156524

Filed: Jan. 10, 2008

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals

"The invention relates to compounds, in particular siRNAs, which inhibit the expression of specific human genes," the patent application's abstract states. "The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier."

Further, the invention "provides a method of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions comprising administering to a subject in need of treatment for such disease or condition and/or symptom the compound or the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject," the abstract adds. "The invention also provides antibodies which inhibit specified human polypeptides and pharmaceutical compositions comprising one or more such antibodies."


Title: RNA Interference-Mediated Inhibition of Hepatitis C Virus Gene Expression Using Short Interfering Nucleic Acid

Number: 20090156528

Filed:
June 11, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention "concerns methods and reagents useful in modulating hepatitis C virus gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic-discovery applications," according to the patent application's abstract. "Specifically, the invention relates to small nucleic acid molecules … capable of mediating RNA interference against hepatitis C virus gene expression and/or activity. The small nucleic acid molecules are useful in the treatment and diagnosis of HCV infection, liver failure, hepatocellular carcinoma, cirrhosis, and any other disease or condition that responds to modulation of HCV expression or activity."


Title: RNAi Inhibition of Alpha-ENaC Expression

Number: 20090156529

Filed: June 16, 2008

Lead Inventor: Gino Van Heeke, Novartis

"The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression, by chemically modified oligonucleotides," the patent application's abstract states.


Title: Use of Inhibitors of Scinderin and/or Ephrin-A1 for Treating Tumors

Number:
20090156531

Filed: Dec. 28, 2006 PCT Filed: Dec. 28, 2006

Inventor:
Salem Chouaib, Institut Gustave Roussy

"The invention relates to the use of inhibitors of the expression or the activity of scinderin and/or of ephrin-A1 inhibitors for increasing the susceptibility of tumor cells to [cytolytic T lymphocytes] killing," the patent application's abstract states. "Such inhibitors may be for instance interfering RNAs targeting the scinderin gene and/or interfering RNAs targeting the ephrin-A1 gene."


Title: RNA Interference-Mediated Inhibition of Stromal Cell-Derived Factor-1 Gene Expression Using Short Interfering Nucleic Acid

Number: 20090156533

Filed: July 8, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of stromal cell-derived factor-1 gene expression and/or activity. The … invention is also directed to compounds, compositions, and methods relating to traits, diseases, and conditions that respond to the modulation of expression and/or activity of genes involved in SDF-1 gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases, and conditions.

"Specifically, the invention relates to small nucleic acid molecules … capable of mediating or that mediate RNA interference (RNAi) against SDF-1 gene expression," it adds. "Such small nucleic acid molecules are useful, for example, in providing compositions for treatment of traits, diseases, and conditions that can respond to modulation of SDF-1 expression in a subject, such as ocular disease, cancer and proliferative diseases, and any other disease, condition, trait, or indication that can respond to the level of SDF-1 in a cell or tissue."


Title: microRNAs for Modulating Herpes Virus Gene Expression

Number: 20090156535

Filed: Sept. 29, 2008

Lead Inventor: Jiri Vanicek, Princeton University

The patent application, its abstract states, claims "an algorithm for identification of microRNA targets within viral and cellular RNA … [as well as] essential herpes virus genes whose transcripts contain one or more targets of miRNAs encoded by herpes viruses or by host cells as predicted by the algorithm, and the use of such targets, miRNAs and their derivatives for modulating viral replication and latency."


Title: AIMP2-DX2 Gene and siRNA Targeting AIMP2-DX2

Number: 20090156536

Filed: Oct. 22, 2008

Lead Inventor: Sunghoon Kim

The invention "relates to a variant of AIMP2 lacking exon 2 gene, named as AIMP2-DX2 gene, which is specifically expressed in cancer cells," according to the patent application's abstract. "The AIMP2-DX2 gene and siRNA targeting AIMP2-DX2 can be successfully used in the development of diagnosis and treatment of cancer."


Title: siRNA Targeting Hypoxia-Inducible Factor 1

Number: 20090156797

Filed: Feb. 2, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed."